Pharma giant Abbott plunked down $110 million in cash last week to acquire AP214, a first-in-class alpha-MSH peptide derivative designed to prevent acute kidney injury (AKI) during major cardiac surgery in patients at increased risk, from privately held Action Pharma A/S, of Aarhus, Denmark.